Online citations, reference lists, and bibliographies.
← Back to Search

Surgical Outcomes And Risk Analysis Of Primary Pulmonary Sarcoma.

Y. Yamada, T. Kaplan, A. Soltermann, I. Schmitt-Opitz, D. Schneiter, W. Weder, I. Inci
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND  Primary pulmonary sarcoma (PPS) is a rare malignant lung neoplasm, and there is very little medical evidence about treatment of PPS. The aim of this study is to clarify the clinical characteristics and therapeutic outcome of patients who underwent surgical resection for PPS. METHODS  We retrospectively reviewed the records of patients who underwent surgical resection for PPS in our institution between 1995 and 2014. Cases who only underwent biopsy were excluded. RESULTS  A total of 24 patients (18 males, 6 females), with a median age of 60 (interquartile range: 44-67) years, were analyzed. The surgical procedures performed in these patients were pneumonectomy (n = 10), lobectomy (n = 11), and wedge resection (n = 3). Complete resection was achieved in 16 patients. The pathological stages (tumor, node, metastases lung cancer classification, 8th edition) of the patients were I (n = 4), II (n = 12), III (n = 2), and IV (n = 5), and there were four cases of lymph node metastasis. The 5-year overall survival rate of the patients was 50% (95% confidence interval [CI]: 29-72). Adverse prognostic factors for overall survival were incomplete resection (hazard ratio [HR]: 4.4, 95% CI: 2.1-42), advanced pathological stage (HR 14, 95% CI: 2.8-66), higher pathological grade (HR 4.5, 95% CI: 1.2-17), and tumor size ≥ 7 cm (HR 4.7, 95% CI: 1.1-21). CONCLUSIONS  Our series of PPS revealed that incomplete resection, advanced pathological stage, higher pathological grade, and tumor size were unfavorable factors for long-term survival.
This paper references
10.1016/S0003-4975(97)00682-6
Primary pulmonary malignant hemangiopericytoma associated with coagulopathy.
Y. C. Wu (1997)
10.1016/S0140-6736(16)30587-6
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
W. Tap (2016)
10.1016/S1010-7940(99)00045-7
Surgical treatment of primary pulmonary sarcomas.
E. Bacha (1999)
10.1016/S1470-2045(17)30624-1
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
H. Tawbi (2017)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1038/labinvest.2017.128
Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers
Robin Veenstra (2018)
10.1097/SLA.0000000000001149
Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma
M. Tan (2016)
10.1016/S0003-4975(99)00398-7
Prognostic factors and results after surgical treatment of primary sarcomas of the lung.
J. Régnard (1999)
10.1016/S0169-5002(02)00303-3
Primary sarcomas of the lung: a clinicopathologic study of 12 cases.
B. Etienne-Mastroianni (2002)
10.1016/j.athoracsur.2015.04.059
Surgical Outcomes of Patients With Stage III Thymoma in the Japanese Nationwide Database.
Y. Yamada (2015)
10.3390/ijms19030739
Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas
K. Nakano (2018)
10.1016/S1010-7940(00)00465-6
Surgical treatment of primary sarcoma of the lung.
H. Porte (2000)
WHO classification of tumours of soft tissue and bone
C. D. Fletcher (2013)
10.1016/0003-4975(94)90476-6
Primary sarcoma of the lung: a clinical study with long-term follow-up.
J. Janssen (1994)
10.1002/MPO.2950010109
Adriamycin: a new effective agent in the therapy of disseminated sarcomas.
R. Benjamin (1975)
10.1093/ejcts/ezt544
Pulmonary malignant peripheral nerve sheath tumour.
I. Inci (2014)
10.1016/S1470-2045(19)30153-6
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
B. Wilky (2019)
10.1186/s40425-017-0301-y
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
R. Groisberg (2017)
10.1046/j.1365-2559.1996.d01-481.x
Primary sarcomas of the lung: a clinicopathological and immunohistochemical study of 14 cases
R. Attanoos (1996)
10.1007/s11864-019-0606-9
First-Line Therapy for Metastatic Soft Tissue Sarcoma
M. Meyer (2019)
10.1016/S1010-7940(03)00024-1
Primary pulmonary sarcomas and carcinosarcomas--postoperative results and comparative survival analysis.
D. Petrov (2003)
10.1097/JTO.0000000000000559
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
R. Rami-Porta (2015)
10.1634/theoncologist.2016-0025
Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Michael J Nathenson (2018)
10.3390/ijms19010019
Assessing the Effectiveness of a Far-Red Fluorescent Reporter for Tracking Stem Cells In Vivo
Jing Zhou (2017)
10.21037/cco.2018.08.04
Next frontiers in systemic therapy for soft tissue sarcoma.
Cheuh-Chuan Yen (2018)
10.1177/1078155218788135
Olaratumab in the management of advanced soft tissue sarcoma
Chrystia M Zobniw (2019)
10.1007/s10585-012-9502-4
Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?
E. Pennacchioli (2012)
10.1371/journal.pone.0082870
Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
J. R. Kim (2013)
10.1200/JCO.1997.15.6.2378
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
S. Patel (1997)
10.1155/2010/506182
Guidelines for the Management of Soft Tissue Sarcomas
R. Grimer (2010)
10.1097/JTO.0b013e318277401f
An Analysis of Patient Characteristics and Clinical Outcomes in Primary Pulmonary Sarcoma
M. Spraker (2013)
10.1016/S1470-2045(14)70063-4
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
I. Judson (2014)
10.1200/JCO.1987.5.6.840
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas.
E. Borden (1987)



Semantic Scholar Logo Some data provided by SemanticScholar